Maravai LifeSciences Holdings, Inc. - MRVI STOCK NEWS

Maravai LifeSciences (NASDAQ: MRVI), a global provider of life science reagents and services, has announced its participation in two major investor conferences in November 2024. The company's executives will participate in fireside chats at the Stifel Healthcare Conference in New York on November 19 and the Jefferies Healthcare Conference in London on November 21. Both presentations will be available via live webcast on the company's Investor Relations website, with archived versions accessible after the events.

Maravai LifeSciences (NASDAQ: MRVI) has signed an agreement to acquire Officinae Bio's DNA and RNA business. The acquisition aims to enhance Maravai's mRNA manufacturing capabilities within TriLink BioTechnologies. Officinae Bio, based in Venice, Italy, offers a proprietary digital platform for therapeutic biological design, enabling rapid mRNA candidate prototyping. The deal will complement Maravai's nucleic acid production services and is expected to close in early 2025. The integration will strengthen TriLink's position as an expert in mRNA design, customization, and manufacturing, while incorporating AI-enabled methodologies for nucleic manufacturing.

Maravai LifeSciences (NASDAQ: MRVI) reported Q3 2024 financial results with revenue of $65.2 million, representing a 2.5% decrease year-over-year. The company posted a net loss of $(176.0) million, including a goodwill impairment of $154.2 million, and Adjusted EBITDA of $12.7 million. Revenue guidance for full-year 2024 was updated to $255.0-265.0 million.

The company announced an agreement to acquire Officinae Bio's DNA and RNA business, expected to close in early 2025. Notable achievements include launching CleanScribe™ RNA Polymerase, commencing their first mRNA Phase II clinical trial contract, and strengthening their CleanCap® patent portfolio.

Maravai LifeSciences (NASDAQ: MRVI), a global provider of life science reagents and services, has announced its plans to release its third quarter 2024 financial and operating results after market close on Thursday, November 7, 2024. The company will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

Interested parties can participate in the conference call by dialing (888) 596-4144 or (646) 968-2525 and referencing Maravai LifeSciences, Conference ID 9502421. Additionally, a live or archived webcast of the call will be available on the "Investors" section of the Maravai website at https://investors.maravai.com.

TriLink BioTechnologies and Alphazyme, both part of Maravai LifeSciences (MRVI), have collaborated to launch CleanScribe™ RNA Polymerase, a novel enzyme that reduces double-stranded RNA (dsRNA) in mRNA production by up to 85%. This innovation helps develop safer, more potent mRNA therapeutics without compromising mRNA yield, capping efficiency, or integrity.

CleanScribe RNA Polymerase catalyzes the in vitro transcription (IVT) of recombinant genes regulated by the T7 promoter, significantly reducing dsRNA formation compared to wild-type T7 RNA Polymerase. The product is ideal for mRNA synthesis, saRNA synthesis, radiolabeled RNA probe preparation, and RNA construct development.

TriLink also offers mRNA capping analogs, raw materials, advanced scale-up capabilities, and expertise in mRNA, oligonucleotide, and enzyme production. With over 25 years of nucleic acid experience, TriLink provides high-quality technology, chemistry, and CDMO services for advancing therapeutics, vaccines, and diagnostics.

Cygnus Technologies and TriLink BioTechnologies, both part of Maravai LifeSciences (NASDAQ: MRVI), have collaborated to launch Cygnus' AccuRes™ Host Cell DNA Quantification Kits. These kits are designed to recover, amplify, and quantify remaining host cell DNA during biologic drug manufacturing, helping to produce safer and more stable vaccines and therapies.

The AccuRes kits use probe-based quantification for specificity and are compatible with any qPCR instrument that detects FAM signal. They offer unparalleled sensitivity with a limit of detection of 0.6 fg/µL. The all-in-one kit includes reagents for DNA extraction, AccuRes PCR master mix, primer/probe mix, and DNA standard.

This collaboration combines Cygnus' proprietary extraction procedure with TriLink's patented CleanAmp® dNTPs and a Hot Start Taq DNA Polymerase, aiming to surpass regulatory standards for host cell DNA levels in biotherapeutics.

Maravai LifeSciences (NASDAQ: MRVI), a global provider of life science reagents and services, has announced its participation in three upcoming investor conferences. CEO Trey Martin will join a panel discussion at the UBS Genomic Medicine Conference on August 14, 2024. Martin and CFO Kevin Herde will participate in fireside chats at the Wells Fargo Healthcare Conference on September 4 and the Morgan Stanley Healthcare Conference on September 5, 2024.

All presentations will be webcast live on the Maravai LifeSciences Investor Relations website, with archived versions available after the events. These conferences provide opportunities for Maravai to showcase its position in the life sciences industry and engage with investors.

Maravai LifeSciences (NASDAQ: MRVI) reported Q2 2024 financial results with revenue of $73.4 million, a 6.5% increase year-over-year. The company experienced a net loss of $(14.5) million and Adjusted EBITDA of $16.9 million. Nucleic Acid Production revenue grew 9.8% to $58.5 million, while Biologics Safety Testing revenue decreased 4.7% to $14.9 million. Maravai reaffirmed its full-year 2024 revenue guidance of $265.0-$285.0 million. The company highlighted progress in product portfolio expansion, market leadership, and scientific innovation, including collaborations, new product launches, and facility updates. Maravai's CEO, Trey Martin, emphasized the company's strong balance sheet and commitment to long-term growth and shareholder value creation.

Maravai LifeSciences (NASDAQ: MRVI) has announced the appointment of CEO William "Trey" Martin, III to its Board of Directors, effective July 31, 2024. This strategic move highlights Martin's leadership, commitment to innovation, and extensive industry experience. Carl Hull, Maravai's co-founder and Executive Chair, expressed confidence in Martin's ability to enhance decision-making and help deliver on the company's return to growth strategy.

Martin, who has served as Maravai's CEO since July 2023, brings over 25 years of executive leadership experience in life sciences. His appointment is expected to strengthen the connection between the Board and day-to-day operations, ensuring responsiveness to key issues. Martin expressed his commitment to building a strong foundation for long-term, sustainable growth of Maravai's businesses.